CancerDrs

Leukemia clinical trials in North Carolina

52 actively recruiting leukemia trials at 24 sites across North Carolina.

Data from ClinicalTrials.gov · last refreshed

Payments from drug makers to the doctors running these trials

For 2 of the trials on this page, the pharmaceutical company funding the trial also disclosed payments to the physicians leading it — public data from the federal CMS Open Payments database. Paying clinical-trial investigators for site work is expected and necessary for industry-funded trials; the scale and source are simply useful context when you're deciding whether to enroll. See the full leukemia transparency page →

Phase 3 Recruiting NIH

Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study

This phase III trial compares early treatment with venetoclax and obinutuzumab versus delayed treatment with venetoclax and obinutuzumab in patients with newly diagnosed high-risk chronic lymphocytic leukemia or small lymphocytic lymphoma.…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT04269902
Sites in North Carolina:
  • UNC Lineberger Comprehensive Cancer Center — Chapel Hill, North Carolina
  • Southeastern Medical Oncology Center-Clinton — Clinton, North Carolina
  • Durham VA Medical Center — Durham, North Carolina
  • Duke University Medical Center — Durham, North Carolina
  • Southeastern Medical Oncology Center-Goldsboro — Goldsboro, North Carolina
View on ClinicalTrials.gov →
Phase 3 Recruiting Network

Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy

This phase III trial studies whether inotuzumab ozogamicin added to post-induction chemotherapy and immunotherapy (chemo-immunotherapy) for patients with High-Risk B-cell Acute Lymphoblastic Leukemia (B-ALL) improves outcomes. Inotuzumab o…

Sponsor: Children's Oncology Group
NCT ID: NCT03959085
Sites in North Carolina:
  • Mission Hospital — Asheville, North Carolina
  • UNC Lineberger Comprehensive Cancer Center — Chapel Hill, North Carolina
  • Carolinas Medical Center/Levine Cancer Institute — Charlotte, North Carolina
  • Novant Health Presbyterian Medical Center — Charlotte, North Carolina
  • Duke University Medical Center — Durham, North Carolina
View on ClinicalTrials.gov →
Phase 3 Recruiting Academic/Other

Testing the Addition of Anti-Cancer Drug Sonrotoclax, to the Standard Treatment Zanubrutinib, for Previously Untreated CLL/SLL

This phase III trial compares the effect of adding sonrotoclax to zanubrutinib versus zanubrutinib alone for the treatment of patients with untreated chronic lymphoblastic leukemia (CLL)/small lymphocytic lymphoma (SLL). Sonrotoclax is in …

Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT07321652
Sites in North Carolina:
  • UNC Lineberger Comprehensive Cancer Center — Chapel Hill, North Carolina
  • Duke University Medical Center — Durham, North Carolina
  • Margaret R Pardee Memorial Hospital — Hendersonville, North Carolina
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)

The purpose of this study is to assess how bleximenib and Venetoclax (VEN)+ Azacitidine (AZA) works as compared to placebo and VEN+AZA alone for the treatment of participants with newly diagnosed Acute Myeloid Leukemia (AML) with a mutatio…

Sponsor: Janssen Research & Development, LLC
NCT ID: NCT06852222
Sites in North Carolina:
  • Atrium Health — Charlotte, North Carolina
  • Novant Health Charlotte — Charlotte, North Carolina
  • Carolina Oncology Specialists — Charlotte, North Carolina
  • Novant Health Winston Salem — Winston-Salem, North Carolina
  • Atrium Health Wake Forest Baptist Comprehensive Cancer Center — Winston-Salem, North Carolina
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL)

Chronic lymphocytic leukemia (CLL) is the most common leukemia (cancer of blood cells). The purpose of this study is to assess the safety of venetoclax in combination with obinutuzumab or acalabrutinib in the treatment of CLL. Adverse even…

Sponsor: AbbVie
NCT ID: NCT06428019
Sites in North Carolina:
  • Atrium Health /ID# 267219 — Charlotte, North Carolina
  • Atrium Health Wake Forest Baptist Medical Center /ID# 273142 — Winston-Salem, North Carolina
View on ClinicalTrials.gov →
Phase 2 Recruiting NIH

MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)

This MyeloMATCH Master Screening and Reassessment Protocol (MSRP) evaluates the use of a screening tool and specific laboratory tests to help improve participants' ability to register to clinical trials throughout the course of their myelo…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05564390
Sites in North Carolina:
  • UNC Lineberger Comprehensive Cancer Center — Chapel Hill, North Carolina
  • Carolinas Medical Center/Levine Cancer Institute — Charlotte, North Carolina
  • Novant Health Presbyterian Medical Center — Charlotte, North Carolina
  • Duke University Medical Center — Durham, North Carolina
  • East Carolina University — Greenville, North Carolina
View on ClinicalTrials.gov →
Phase 2 Recruiting NIH

Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)

This phase II MyeloMATCH treatment trial compares the usual treatment of azacitidine and venetoclax to the combination treatment of azacitidine, venetoclax and gilteritinib in treating older and unfit patients with acute myeloid leukemia a…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT06317649
Sites in North Carolina:
  • UNC Lineberger Comprehensive Cancer Center — Chapel Hill, North Carolina
  • Carolinas Medical Center/Levine Cancer Institute — Charlotte, North Carolina
  • Duke University Medical Center — Durham, North Carolina
  • East Carolina University — Greenville, North Carolina
  • Wake Forest University Health Sciences — Winston-Salem, North Carolina
View on ClinicalTrials.gov →
Phase 2 Recruiting NIH

A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)

This phase II trial studies the effect of nivolumab in combination with blinatumomab compared to blinatumomab alone in treating patients with B-cell acute lymphoblastic leukemia (B-ALL) that has come back (relapsed). Down syndrome patients…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT04546399
Sites in North Carolina:
  • Mission Hospital — Asheville, North Carolina
  • UNC Lineberger Comprehensive Cancer Center — Chapel Hill, North Carolina
  • Carolinas Medical Center/Levine Cancer Institute — Charlotte, North Carolina
  • Duke University Medical Center — Durham, North Carolina
  • East Carolina University — Greenville, North Carolina
View on ClinicalTrials.gov →
Phase 2 Recruiting NIH

Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)

This phase II MyeloMATCH treatment trial compares cytarabine with daunorubicin versus cytarabine with daunorubicin and venetoclax versus venetoclax with azacitidine for the treatment of younger patients with intermediate risk acute myeloid…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05554393
Sites in North Carolina:
  • Carolinas Medical Center/Levine Cancer Institute — Charlotte, North Carolina
  • Novant Health Presbyterian Medical Center — Charlotte, North Carolina
  • Duke University Medical Center — Durham, North Carolina
  • East Carolina University — Greenville, North Carolina
  • Novant Health Forsyth Medical Center — Winston-Salem, North Carolina
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Network

Study to Test OBI-3424 in Patients With T-Cell Acute Lymphoblastic Leukemia (T-ALL) or T-Cell Lymphoblastic Lymphoma (T-LBL)

This phase I/II trial studies the safety, side effects and best dose of OBI-3424 and how well it works in treating patients with T-cell acute lymphoblastic leukemia or T-cell lymphoblastic lymphoma that has come back (relapsed) or does not…

Sponsor: SWOG Cancer Research Network
NCT ID: NCT04315324
Sites in North Carolina:
  • Duke University Medical Center — Durham, North Carolina
View on ClinicalTrials.gov →
Phase 2 Recruiting NIH

A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)

This pilot trial assesses the effect of the combination of blinatumomab with dasatinib or imatinib and standard chemotherapy for treating patients with Philadelphia chromosome positive (Ph+) or ABL-class Philadelphia chromosome-like (Ph-li…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT06124157
Sites in North Carolina:
  • Mission Hospital — Asheville, North Carolina
  • UNC Lineberger Comprehensive Cancer Center — Chapel Hill, North Carolina
  • Carolinas Medical Center/Levine Cancer Institute — Charlotte, North Carolina
  • Duke University Medical Center — Durham, North Carolina
  • Wake Forest University Health Sciences — Winston-Salem, North Carolina
View on ClinicalTrials.gov →
Phase 2 Recruiting NIH

Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia

This phase II trial tests the addition of venetoclax and/or blinatumomab to usual chemotherapy for treating infants with newly diagnosed acute lymphoblastic leukemia (ALL) with a KMT2A gene rearrangement (KMT2A-rearranged \[R\]) or without…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT06317662
Sites in North Carolina:
  • UNC Lineberger Comprehensive Cancer Center — Chapel Hill, North Carolina
  • Carolinas Medical Center/Levine Cancer Institute — Charlotte, North Carolina
  • Duke University Medical Center — Durham, North Carolina
  • East Carolina University — Greenville, North Carolina
  • Wake Forest University Health Sciences — Winston-Salem, North Carolina
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)

A phase 1/2 dose escalation / dose expansion study of Enzomenib (DSP-5336) in patients with acute leukemia.

Sponsor: Sumitomo Pharma America, Inc.
NCT ID: NCT04988555
Sites in North Carolina:
  • UNC Hospital — Chapel Hill, North Carolina
  • Duke University — Durham, North Carolina
  • Atrium Wake Forest Baptist Medical Center — Winston-Salem, North Carolina
View on ClinicalTrials.gov →
Phase 2 Recruiting Academic/Other

The EndRAD Trial: Eliminating Total Body Irradiation (TBI) for NGS-MRD Negative Children, Adolescents, and Young Adults With B-ALL

This study will evaluate the use of non- TBI (total body irradiation) conditioning for B-ALL patients with low risk of relapse as defined by absence of NGS-MRD (next generation sequencing minimal residual disease) before receiving a hemato…

Sponsor: Pediatric Transplantation & Cellular Therapy Consortium
NCT ID: NCT03509961
Sites in North Carolina:
  • Atrium Health - Levine Cancer Center — Charlotte, North Carolina
View on ClinicalTrials.gov →
Phase 2 Recruiting Industry

A Study of Tagraxofusp in Combination With Venetoclax and Azacitidine in Adults With Untreated CD123+ Acute Myeloid Leukemia Who Cannot Undergo Intensive Chemotherapy

This study will be divided into 2 parts (Part 1 and Part 2). Part 1 will evaluate 2 doses of tagraxofusp (9 and 12 micrograms/kilogram/day \[μg/kg/day\]), used in combination with venetoclax and azacitidine, to determine the dose for Part …

Sponsor: Stemline Therapeutics, Inc.
NCT ID: NCT06456463
Sites in North Carolina:
  • Novant Health Presbyterian Medical Center — Charlotte, North Carolina
  • Novant Health Derrick L Davis Cancer Center — Winston-Salem, North Carolina
View on ClinicalTrials.gov →
Phase 2 Recruiting Industry

A Study Evaluating the Efficacy and Safety of Pirtobrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

The main purpose of Part 1 of this study is to assess the efficacy and safety of 3 dose levels of Pirtobrutinib in participants with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), who have received 1-3 lines of tre…

Sponsor: Loxo Oncology, Inc.
NCT ID: NCT06588478
Sites in North Carolina:
  • East Carolina University — Greenville, North Carolina
View on ClinicalTrials.gov →
Phase 2 Recruiting Industry

A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)

This is a study for patients with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who have previously received treatment with a BTK inhibitor (covalent and non-covalent) and a BCL-2 inhibito…

Sponsor: Nurix Therapeutics, Inc.
NCT ID: NCT07221500
Sites in North Carolina:
  • Duke University — Durham, North Carolina
  • Novant Health Cancer Institute — Winston-Salem, North Carolina
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Academic/Other

Study of Biomarker-Based Treatment of Acute Myeloid Leukemia

This screening and multi-sub-study Phase 1b/2 trial will establish a method for genomic screening followed by assigning and accruing simultaneously to a multi-study "Master Protocol (BAML-16-001-M1)." The specific subtype of acute myeloid …

Sponsor: Beat AML, LLC
NCT ID: NCT03013998
Sites in North Carolina:
  • UNC Hospitals, University of North Carolina at Chapel Hill — Chapel Hill, North Carolina
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Tuspetinib (HM43239) in Patients With Relapsed or Refractory Acute Myeloid Leukemia

The main purpose of this study is to identify a safe and potentially effective dose of tuspetinib to be used in future studies in study participants diagnosed with acute myeloid leukemia (AML), myelodysplastic syndromes with increased blas…

Sponsor: Aptose Biosciences Inc.
NCT ID: NCT03850574
Sites in North Carolina:
  • Duke University Medical Center — Durham, North Carolina
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Academic/Other

A Study of Revumenib and Mezigdomide in People With Leukemia

The purpose of this study is to find out whether the combination of mezigdomide and revumenib is a safe treatment for people with relapsed or refractory KMT2A-r, NUP98-r, and NPM1-m acute leukemias.

Sponsor: Memorial Sloan Kettering Cancer Center
NCT ID: NCT07356154
Sites in North Carolina:
  • University of North Carolina (Data Collection Only) — Chapel Hill, North Carolina
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

A Study to Evaluate Safety, PK, PD and Efficacy of AZD5492, a T Cell-engaging Antibody Targeting CD20 in Subjects With R/R B-Cell Malignancies.

This is a Phase I/II study designed to evaluate if experimental T cell engaging antibody targeting CD20 AZD5492 is safe, tolerable and efficacious in participants with Relapsed or Refractory B-Cell Malignancies.

Sponsor: AstraZeneca
NCT ID: NCT06542250
Sites in North Carolina:
  • Research Site — Charlotte, North Carolina
  • Research Site — Winston-Salem, North Carolina
View on ClinicalTrials.gov →
Phase 2 Recruiting Academic/Other

Phase 2 Study of Glofitamab Monotherapy & With Polatuzumab Vedotin, Pirtobrutinib, or Atezolizumab in Richter's Transformation

This research is being done to evaluate Glofitamab by itself or in combination with Polatuzumab Vedotin, Pirtobrutinib, or Atezolizumab as possible treatments for Chronic Lymphocytic Leukemia (CLL) that has transformed into Richter's Trans…

Sponsor: Christine Ryan
NCT ID: NCT06043674
Sites in North Carolina:
  • The University of North Carolina at Chapel Hill — Chapel Hill, North Carolina
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

The Safety and Tolerability of LBS-007 in Patients With Relapsed or Resistant Acute Leukaemias

The most common types of acute leukaemia are acute lymphoblastic leukaemia (ALL) and acute myeloid leukaemia (AML). AML is a heterogenous clonal disorder of haemopoietic progenitor cells and the most common and severe malignant leukemia in…

Sponsor: Lin BioScience, Inc
NCT ID: NCT05756322
Sites in North Carolina:
  • UNC Hospitals, The University of North Carolina at Chapel Hill — Chapel Hill, North Carolina
View on ClinicalTrials.gov →
Phase 2 Recruiting Academic/Other

Adding Dasatinib Or Venetoclax To Improve Responses In Children With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (ALL) Or Lymphoma (T-LLY) Or Mixed Phenotype Acute Leukemia (MPAL)

This is a clinical trial testing whether the addition of one of two chemotherapy agents, dasatinib or venetoclax, can improve outcomes for children and young adults with newly diagnosed T-cell acute lymphoblastic leukemia and lymphoma or m…

Sponsor: St. Jude Children's Research Hospital
NCT ID: NCT06390319
Sites in North Carolina:
  • Novant Health Presbyterian Hemby Children's Hospital — Charlotte, North Carolina
View on ClinicalTrials.gov →

Showing 25 of 52 trials with sites in North Carolina. See all leukemia trials →

Medical disclaimer: This page aggregates public ClinicalTrials.gov data. It is not medical advice. Always confirm eligibility and enrollment details with the trial site or your oncologist.

Source: ClinicalTrials.gov API v2 · Last checked: 2026-07-27